A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

I4T-MC-JVDJ -

The main purpose of this study is to evaluate the safety of ramucirumab plus MEDI4736 in participants with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies including gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Stomach Cancer, Lung Cancer, Liver Cancer
What the trial is testing?
Durvalumab, Ramucirumab
Could I receive a Placebo?
No
Enrollment Goal
85
Trial Dates
Feb 19, 2016 - Jan 13, 2021
How long will I be in the trial?
Your participation could range from several months to several years depending on how you and your tumor respond.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have measurable metastatic disease or locally advanced and unresectable disease

  • Participant must be willing to provide tumor tissue for biomarker analysis

Participants Must Not:

  • Participant must not have known brain metastases

  • Participant must not have active or prior documented autoimmune disease within the past 24 months

  • Participant must not have HIV, AIDS-related illness, or a history of immunodeficiency

  • Participant with hepatitis B or hepatitis C infection may not be eligible depending on your tumor type

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.